

Role of Angiotensin II in Hepatic Inflammation through MAPK Pathway: A Review

Md Mohabbulla Mohib¹,
Istiaque Hasan¹,
Wahida Khan Chowdhury²,
Nafees Uddin Chowdhury³,
Sarif Mohiuddin⁴,
Md Abu Taher Sagor¹,
Hasan Mahmud Reza¹ and
Md. Ashraful Alam¹

Abstract

Renin Angiotensin system (RAS) regulates multiple physiological, pharmacological and pathological functions throughout the body by interacting with angiotensin II (Ang II) receptor type 1 (AT₁R) and Ang II receptor type 2 (AT₂R). However, Ang II is being blamed for damaging several organs like kidney, heart, adrenal cortex, smooth muscles, brain, pancreas, endothelial function and liver. On the other hand, mitogenactivated protein kinase (MAPK) signal transduction pathways are normally observed everywhere and extremely regulated process for a eukaryotic cell cycle. Like Ang II, MAPK also contributes several physiological and pathological functions once it is activated. Moreover, MAPK cascade is also considered as a key signaling pathway that strictly controls various stimulated cellular processes, including proliferation, differentiation, inflammation, fibrosis and apoptosis. We have explained that how Ang II is responsible for MAPK activation and its further consequences in cytoplasm and nucleus for regulation of several inflammatory and proinflammatory cytokines. Overall, all signaling components may appear as an important regulatory messenger in the induction of hepatic cellular inflammation, and therefore, it could serve as targets for therapeutic intervention diseases like hepatitis and other related complications.

Keywords: Liver dysfunctions; RAS; AT₁R; MAPK; Inflammation

Received: February 23, 2016; **Accepted:** April 29, 2016; **Published:** May 06, 2016

Introduction

Both acute and chronic hepatic dysfunctions are increasing globally which contributes to hepatic failure [1]. Consumption of alcoholic beverages, fatty foods, taking unnecessary over the counter (OTC) drugs and leading a sedentary lifestyle serves as the main contributing factor for the development of hepatic damages [2]. As the extent of mortality and morbidity is increasing at an alarming rate, consequently it is capturing the attention of current public health care professionals [3]. Drugs induced liver toxicity has often been observed when a therapy fails or shows harmful adverse drug reaction (ADR) [4]. However, in most of the cases, normal hepatic functions are being hampered by either free radicals mediated oxidative stress or inflammatory cytokines [5]. Taken together, hepatic disturbances often assist in collagen production, extra cellular matrix deposition [6], mast cell accumulation [7], hemeoxygenase degradation [8], migration and infiltration of various immune cells [9] which lead to cirrhosis, hepatitis, hypertrophy, carcinoma and liver failure [10].

Liver dysfunction is often observed due to overproduction of Ang II in the liver, activating local RAS that helps in free radicals

generation, vascular damage, cellular growth and apoptosis through immune cell migration [11]. In addition, Ang II concentration in serum is found higher in patients suffering from chronic hepatitis C or prone to genetic polymorphism [12]. Inside the liver, Ang II generally binds with AT₁R which activates Hepatic stellate cells (HSC) that further initiates its downstream pathway [13]. Furthermore, Ang II-AT₁R interaction also activates local macrophages to release various cytokines like nuclear factor and-κβ (NF-κβ) macrophage inflammatory protein (MIP), SMAD,

- 1 Department of Pharmaceutical Sciences, North South University, Dhaka-1229, Bangladesh
- 2 Department of Dermatology, Shahabuddin Medical College and Hospital, Gulshan, Dhaka-1229, Bangladesh
- 3 Department of Prosthodontics, Kumudini Woman's Medical College, Dhaka-1229, Bangladesh
- 4 Department of Anatomy, Pioneer Dental College and Hospital, Dhaka-1229, Bangladesh

Corresponding author: Md Abu Taher Sagor

✉ sagor2008nsu@gmail.com

Department of Pharmaceutical Sciences,
North South University, Bangladesh.

Tel: +8801719130130

Citation: Mohib M Md, Hasan I, Chowdhury WH, et al. Role of Angiotensin II in Hepatic Inflammation through MAPK Pathway: A Review. J Hep. 2016, 2:2

Cyclooxygenase 2 and other chemokines [14,15]. Study also revealed that mice lacking AT₁R genetically were able to attenuate hepatic inflammation [16]. Other studies also discussed that hepatic Ang II also attracts several downstream molecules like α -smooth muscle actin, β -actin, human leukocyte antigen (HLA), and other chemokines [18,19].

Mitogen activated protein kinases (MAPKs) have been extensively studied and found to be responsible for several types of inflammation through AT₁R interaction [20]. MAPK also plays a pivotal role in the progression of several pathophysiologicals like hepatitis, fibrosis, iron deposition, hypertrophy and apoptosis [21]. It is noticed that MAPK, which is a signaling pathway is activated when an extracellular molecules binds on it and then transmitting signals to the intracellular machinery process through G protein-coupled receptor [22]. Interestingly, MAPK has been also blamed as stress activated protein kinases (SAPKs), mostly activated by environmental as well as chemical stress, that further plays a key role in the processing of different chemical and cellular responses [23]. Surprisingly, it is experimented that MAPK is solely responsible for hepatic inflammatory signaling like

nuclear factor- κ B, interleukin-6, endothelin-1 (ET-1), activating protein-1 too [24]. Furthermore, MAPK mediated signaling significantly contribute to several cancers [25,26]. Not only for clinical significance but also for therapeutic approaches, MAPK and Ang II-AT₁R interaction have been exclusively important for elucidating several diseases as well as to make a target molecule against MAPK. Therefore, this review will try to explore the molecular mechanisms inside liver involving various inflammatory signaling that leads to hepatic inflammation.

Angiotensin II and MAPK

RAS is a very wide and important pathway which coordinate several biological functions like regulation of blood pressure, cellular growth, production of extra cellular matrix, stimulation of proinflammatory or inflammatory cytokines and initiates apoptosis if necessary [27]. This pathway is generally activated once renin is available inside circulation. Renin, which is a protease enzyme produced from the kidney, converts liver angiotensinogen to angiotensin I. Furthermore, angiotensin I is converted to Angiotensin I and Angiotensin II when either




Figure 1 Production of AngiotensinII and related organ dysfunctions.

pulmonary ACE or tissue chymase or cathepsin are available via G protein-coupled receptor (**Figure 1**) [28]. So far, several types of angiotensin (I-XII) have been isolated from various models and those are activated through AT₁R and AT₂R [29]. Angiotensin can be activated in both circulation and tissue due to the availability of its receptors throughout the body [30]. It has been also noticed that activation of AT₂R often brings some protective effects like reduced inflammation via epoxyeicosatrienoic acid and by inhibiting nuclear factor- κ B [31]. Another study explained that Ang II induce arterial pressure can be reduced by the activation of AT₂R in rat model [32]. A cross study has also been found which explained that deletion of AT₂R may protect from diet-induced obesity and insulin resistance in rats [33].

On the other hand it is highly established that Ang II-AT₁R binding mostly signals through MAPK pathway that promotes cellular growth and inflammation [34]. However, MAPK often serves a huge number of fundamental cellular processes to exchange extracellular and intracellular information [35]. Within the endoplasmic reticulum (ER), generally three core types of MAPK are found which are MAP3K, MAP2K, and MAPK. Beside this, downstream kinase (MAPKAPK) and upstream kinase (MAP4K) are also noticed. Inside the mammalian MAPK cascade, four different kinds of MAPK were isolated and named as MAPK p38, ERK5, cJun N terminal kinase (JNK) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) respectively [36].

Ang II and MAPK in hepatic free radicals generation

Free radicals are highly reactive molecules which directly damage cell membrane, cytoplasm as well as nucleus [37]. The prime members of this family are reactive oxygen species and reactive nitrogenous species that hamper the normal cellular activity and produces oxidative stress [38]. However, free radical as well as oxidative stress mediated hepatic dysfunction has been noticed enormously by disturbing liver Cytochrome p₄₅₀ system [39]. Oxidative stress markers have also been identified inside the serums who were suffering from chronic hepatitis C [40]. Furthermore, hepatic tissue injuries are very common when free radicals like \bullet OH, \bullet O₂, and H₂O₂ are generated inside liver [41]. Although Ang II is mainly responsible for controlling blood pressure, it also significantly generates free radical when it is attached with AT₁R [42]. Study also suggested that Ang II-AT₁R interaction stimulates NAD(P)H oxidase (NOX) and generates ROS and RNS which further stimulates several proinflammatory cytokines [11,43]. Mitogen activate protein kinase also participates in generation of free radicals which is mostly noticed via NAD(P)H oxidase (NOX) 4 and AKT1-AKT2 (protein kinase B) pathway [44,45]. Another study explained that activation of p38MAPK was observed in ATP depleted hepatic stellate cells (HSCs) culture. The study also described that p38MAPK depended reactive oxygen species (ROS) declined number of normal HSCs [46,47]. One of the crucial studies explored that reactive oxygen species contribute significantly in development of several cancers by stimulating different cytokines [48].

Ang II and MAPK in diabetes

Diabetes, a heterogeneous metabolic disorders which not

only affects pancreas but also hampers normal functioning of liver [49]. Nonalcoholic liver diseases and diabetes are the two major components of metabolic syndrome [50]. Inside the liver, high glucose concentration may alter cellular homeostasis [51] and might induce several pathological events [52]. Taken together, the complication of diabetes can activate hepatic Ang II [53] which further induces MAPK family [54] that possesses several inflammatory cytokines like activated protein-1, tumor necrosis factor- α , and nuclear factor- κ B, and many others [55]. Inflammatory cytokines further responsible for the development of liver cirrhosis, cancer and liver failure if not treated with care [56]. However, chronic diabetic status also triggers collagen and extracellular matrix production in liver which further develop hepatic fibrosis [57,58].

Ang II and MAPK in hepatic inflammation

Biological subjects are always exposed to its surrounding environment, at the same time they also need food and air to survive. Unfortunately, environment carries several foreign harmful elements which often invade inside biological system and activates host immunity [65]. On the other hand, liver serves various protective roles by producing several growth factors, antibody and other immune components to fight against harmful stimuli [66]. Once those foreign elements invade into hepatic tissue, liver immediately attracts neutrophil, T cell, local macrophages, β integrin and natural killer cells [67]. The evidences for the role of Ang II and MAPKs in the development of hepatic inflammation are summarized in **Table 1**. It is highly suggested that Angiotensin II often stimulates immune cells by activating kupffer cell to invite monocytes, killer cells, tumor necrosis factor and interleukins [68]. Local hepatic renin angiotensin system is also regulated by chronic liver injury which simultaneously activates some events such as recruitment of inflammatory cells and generation of free radicals [69]. Angiotensin related hepatic inflammation often showed elevated level of liver marker such as AST, ALP and ALT which confirms hepatic tissue injury [70]. Study also explored that MAPK which is activated by Ang II solely participates in hepatic inflammation [71]. Another study disclosed that MAPK-JNKs remarkably serve inflammation [72]. A hypothetical mechanism for Ang II and MAPKs mediated inflammatory response has been proposed in **Figure 2**.

New promising molecules against MAPK family

Researchers always try hard to develop a potent molecule against any kind of pathogenesis. Various molecules have been tested against angiotensin and related family. There is no such potent MAPK inhibitor has been established yet. Some good activities have been showed by few molecules but they need proper trial [73,74] and their effects on various experimental animal models are summarized in **Table 2**. BI78D3, an inhibitor of JNK showed prevention of JNK phosphorylation and ameliorates JNK dependent liver damage [75]. Another JNK inhibitor SP600125 showed promising effect on preventing the JNK expression and its activity in HeLa cells [76]. Furthermore, animal studies also showed that CNI1493 may prevent p38 MAP kinase signalling cascade and reduced TNF- α level in collagen induced arthritis rats [77]. Inhibition of p38 MAP kinase signalling cascade by SB203580

also restored the development and cellular proliferation in developing liver [78]. However, these newly developed molecules showed promising results in various *in vitro* and *in vivo* assays,

their side effects and adverse drug reaction profiles are not established fully. A selective inhibitor of p38 mitogenactivated protein kinase, BIRB796, is such a molecule which activates the

Table 1 Role of Ang II on hepatic inflammation via several members of MAPK

family.	Models	Outcomes of the study	References
HSCT6 cells		Ang II caused HSC to produce ECM via activation of ERK and cJun.	[59]
		Expression of AT ₁ R found high due to Ang II.	
Male Sprague Dawley rats		Angiotensin (1-7) blocked liver inflammation by inhibiting MAPK expression.	[60]
		Reduced TLR-4 and NF-κβ expression in liver.	
Male Sprague Dawley rats		Activation of liver injury is mediated by MAPK over expression.	[61]
		Ang II induces oxidative stress, hepatic inflammation, and vascular damage and thus resulting liver injury.	
Male Sprague Dawley rats		Ang II increased phosphorylation of cJun and ERK-2.	[11]
		It signaled proinflammatory cytokines via MAPK signaling.	
Male Sprague Dawley rats		MAPK family caused proinflammatory cytokine synthesis such as IL-6, and TNF-α in HSCs.	[62,63]
Sprague Dawley wild-type rats		Ang II causes the activation of Janus Kinase 2 in liver dysfunction via several cytokines productions.	[64]




Figure 2 The possible pathway describes when Angiotensin 2 binds with angiotensin type 1 receptor it activates the mitogen activated protein kinase (MAPK), at the same time generation of free radicals and NADPH oxidase (NOX4) also gets activated, but these molecules also activates MAPK. Activation of NF-κβ is caused either by JNK-JUN pathway or by p38-IKK-IKB pathway; these activation will facilitate the production of mRNA of Proinflammatory cytokines such as TGF-β, TNF-α, and IL-6. Produced Interleukin (IL-6) binds with IL-6 receptor, and activates STAT-3 through JAK-STAT pathway to produce ICAM, MCP which assist in inflammation. Tumor Necrosis Factor (TNF-α) after binding with its receptor within the cell membrane activates Tumor necrosis factor receptor type 1 associated DEATH domain (TRADD) which triggers TNF receptor-associated factor 2 (TNFR2) that stimulates Activated protein (AP 1) by p38MK2 pathway to initiate the production of proinflammatory cytokines.

Table 2 Role of new molecules on MAPK family.

Molecules	Models	Outcome of the study	References
BI78D3	Diabetic Mice and Human prostate tissue	Inhibited the phosphorylation of JNK substrates in the cell Blocked JNK dependent liver damage and restores insulin sensitivity.	[75,80]
SP600125	HeLa cell culture	Inhibited JNK catalytic activity	[76]
CNI1493	Rat model	Reduced TNF- α and macrophage mediated inflammation through p38 MAP kinase signalling cascade	[77]
SB203580	Fetal rat hepatocytes	Inhibited p38 mitogen-activated protein kinase pathway in hepatocyte	[78]
BIRB796 Male mice The selective activity of BIRB796 induced nuclear factor (erythroid -derived 2)- like 2 signaling in the liver. [79]			

nuclear factor (erythroid derived 2) like 2 signaling pathway [79]. However, a reactive intermediate of BIRB796 could be found both in mouse and human liver microsomes which is responsible for the development of BIRB796's hepatotoxicity [79].

Conclusion and Future Directions

Ang II induced hepatic inflammation via MAPK suggests several pathways. Firstly, Ang II interacts with AT₁R, stimulates Gprotein couple receptor (GPCR) and then activates MAPK, resulted free radicals generation, later sends stimulation for inflammatory and proinflammatory molecules and production of other growth factors which finally contribute hepatic inflammation or hepatitis. MAPKs are important signaling molecules in several pathways in liver physiology and disease pathogenesis. In many pathologic processes, JNK1 is found responsible. MAPK and other members of this family regulate multiple pathophysiologic processes, including liver cell death, steatosis, inflammation, fibrosis and many more. So a therapy must be established against hepatitis induced by MAPK. Several other molecules are already in development processes which need to be properly testified through clinical trial.

References

- 1 Wang HJ, Gao B, Zakhari S, Nagy LE (2012) Inflammation in alcoholic liver disease. *Annu Rev Nutr* 32: 343-368.
- 2 Novo E, Parola M (2012) The role of redox mechanisms in hepatic chronic wound healing and fibrogenesis. *Fibrogenesis Tissue Repair* 5: S4.
- 3 Hernandez-Gea V, Friedman SL (2011) Pathogenesis of liver fibrosis. *Annu Rev Pathol* 6: 425-456.
- 4 Lee WM (2003) Drug-induced hepatotoxicity. *N Engl J Med* 349: 474-485.
- 5 Lee GP, Jeong WI, Jeong DH, Do SH, Kim TH, et al. (2005) Diagnostic evaluation of carbon tetrachloride-induced rat hepatic cirrhosis model. *Anticancer Res* 25: 1029-1038.
- 6 Sagor AT, Chowdhury MRH, Tabassum N, Hossain H, Rahman MM, et al. (2015) Supplementation of fresh ucche (*Momordica charantia* L. var. *muricata* Willd) prevented oxidative stress, fibrosis and hepatic damage in CCl4 treated rats. *BMC Complement Altern Med* 15: 115.
- 7 Reza HM, Sagor MAT, Alam MA (2015) Iron deposition causes oxidative stress, inflammation and fibrosis in carbon tetrachloride induced liver dysfunction in rats. *Bangladesh Journal of Pharmacology* 10: 152159.
- 8 Chowdhury MR, sagor MA, Tabassum N, Poto MA, Hossain H, et al. (2015) Supplementation of Citrus maxima peel powder prevented oxidative stress, fibrosis and hepatic damage in carbon tetrachloride (CCl4) treated rats. *Evid Based Complement Alternate Med*.
- 9 Sagor MAT (2015) *World journal of pharmaceutical research* 2015.
- 10 Ekor M, Odewabi AO, Kale OE, Oritogun KS, Adesanoye OA, et al. (2011) Pharmacologic inhibition of renin-angiotensin system did not attenuate hepatic toxicity induced by carbon tetrachloride in rats. *Human & experimental toxicology* 30: 1840-1848.
- 11 Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, et al. (2003) Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. *American Journal of Physiol Gastrointest Liver Physiol* 285: G642-G651.
- 12 Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, et al. (2000) Host genetic factors influence disease progression in chronic hepatitis C. *Hepatology* 31: 828-833.
- 13 Li X, Meng Y, Wu P, Zhang Z, Yang X (2007) Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat. *Regul Pept* 138: 15-25.
- 14 Cox S, Abu-Ghannam N, Gupta S (2010) An assessment of the antioxidant and antimicrobial activity of six species of edible Irish seaweeds. *International Food Research Journal* 17: 205-220.
- 15 Douillette A, Bibeau-Poirier A, Gravel SP, Clément JF, Chénard V, et al. (2006) The proinflammatory actions of angiotensin II are dependent on p65 phosphorylation by the I-kappaB kinase complex. *J Biol Chem* 281: 13275-13284.
- 16 Yang L, Bataller R, Dulyx J, Coffman TM, Ginès P, et al. (2005) Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. *J Hepatol* 43: 317-323.
- 17 Rahim SM, Taha EM, Al-janabi MS, Al-douri BI, Simon KD, et al. (2014) Hepatoprotective Effect Of Cymbopogon Citratus Aqueous Extract Against Hydrogen Peroxide-Induced Liver Injury In Male Rats. *African Journal of Traditional Complementary and Alternative Medicines* 11: 447-451.
- 18 Kim MY, Baik SK, Park DH, Jang YO, Suk KT, et al. (2008) Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model. *J Gastroenterol* 43: 889-896.
- 19 Türkay C, Yönm O, Arici S, Koyuncu A, Kanbay M (2008) Effect of angiotensin-converting enzyme inhibition on experimental hepatic fibrogenesis. *Dig Dis Sci* 53: 789-793.
- 20 Meng Y, Yu CH, Li W, Li T, Luo W, et al. (2014) Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF- κ B pathway. *Am J Respir Cell Mol Biol* 50: 723-736.
- 21 Seki E, Brenner DA, Karin M (2012) A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. *Gastroenterology* 143: 307-320.
- 22 Dong C, Davis RJ, Flavell RA (2002) MAP kinases in the immune response. *Annual review of immunology* 20: 55-72.
- 23 Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA (2009) p38(MAPK): stress responses from molecular mechanisms to therapeutics. *Trends Mol Med* 15: 369-379.
- 24 Ruiz-Ortega M, Lorenzo O, Ruperez M, Suzuki Y, Egido J (2001) Angiotensin II activates nuclear transcription factor-kappaB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice. *Nephrology Dialysis Transplantation* 16: 27-33.
- 25 Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, et al. (2012) EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. *Cancer Discov* 2: 227-235.
- 26 Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, et al. (2012) Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. *Cancer research* 72: 1878-1889.
- 27 Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, et al. (2002) Endothelial function and oxidative stress in renovascular hypertension. *N Engl J Med* 346: 1954-1962.
- 28 Savoia C, Burger D, Nishigaki N, Montezano A, Touyz RM (2011) Angiotensin II and the vascular phenotype in hypertension. *Expert Rev Mol Med* 13: e11.
- 29 de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T (2000) International union of pharmacology. XXIII. The angiotensin II receptors. *Pharmacol Rev* 52: 415-472.
- 30 Steckelings UM, Kaschina E, Unger T (2005) The AT2 receptor--a matter of love and hate. *Peptides* 26: 1401-1409.
- 31 Rompe F, Artuc M, Hallberg A, Alterman M, Ströder K, et al. (2010) Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. *Hypertension* 55: 924-931.
- 32 Sampson AK, Moritz KM, Jones ES, Flower RL, Widdop RE, et al. (2008) Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats. *Hypertension* 52: 666-671.
- 33 Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, et al. (2005) Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. *Diabetes* 54: 991-999.
- 34 Reudelhuber TL (2010) Prorenin, Renin, and their receptor: moving targets. *Hypertension* 55: 1071-1074.

- 35 Pimienta G, Pascual J (2007) Canonical and alternative MAPK signaling. *Cell Cycle* 6: 2628-2632.
- 36 Coulombe P, Meloche S (2007) Atypical mitogen-activated protein kinases: structure, regulation and functions. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research* 1773: 1376-1387.
- 37 Sagor MA, Tabassum N, Potal MA, Alam MA (2015) Xanthine oxidase inhibitor, Allopurinol, prevented oxidative stress, fibrosis and myocardial damage in isoproterenol induced aged rats. *Oxid Med Cell Longev*.
- 38 Alam MA, Chowdhury MR, Jain P, Sagor MA, Reza HM (2015) DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats. *Diabetol Metab Syndr* 7: 107.
- 39 Weber LW, Boll M, Stampfl A (2003) Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. *Crit Rev Toxicol* 33: 105-136.
- 40 Metwally MA, Zein CO, Zein NN (2004) Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. *Am J Gastroenterol* 99: 286-291.
- 41 Zhu W, Fung PC (2000) The roles played by crucial free radicals like lipid free radicals, nitric oxide, and enzymes NOS and NADPH in CCl₄-induced acute liver injury of mice. *Free Radic Biol Med* 29: 870-880.
- 42 Colmenero J, Bataller R, Sancho-Bru P, Domínguez M, Moreno M, et al. (2009) Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. *Am J Physiol Gastrointest Liver Physiol* 297: G726-734.
- 43 Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, et al. (2003) NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. *The Journal of clinical investigation* 112: 1383-1394.
- 44 Jang YY, Sharkis SJ (2007) A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. *Blood* 110: 3056-3063.
- 45 Juntilla MM, Patil VD, Calamito M, Joshi RP, Birnbaum MJ, et al. (2010) AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species. *Blood* 115: 4030-4038.
- 46 Barzilai A, Rotman G, Shiloh Y (2002) ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. *DNA Repair (Amst)* 1: 3-25.
- 47 Benhar M, Dalyot I, Engelberg D, Levitzki A (2001) Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. *Molecular and cellular biology* 21: 6913-6926.
- 48 Kobayashi CI, Suda T (2012) Regulation of reactive oxygen species in stem cells and cancer stem cells. *J Cell Physiol* 227: 421-430.
- 49 Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, et al. (2010) Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network for United Network for Organ Sharing database. *Transplantation* 89: 1134-1140.
- 50 Farrell GC (2009) The liver and the waistline: Fifty years of growth. *J Gastroenterol Hepatol* 24 Suppl 3: S105-S118.
- 51 CAHILL GF Jr, Ashmore J, Earle AS, Zottu S (1958) Glucose penetration into liver. *Am J Physiol* 192: 491-496.
- 52 Qureshi K, Abrams GA (2007) Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. *World J Gastroenterol* 13: 3540-3553.
- 53 Leehey DJ, Singh AK, Alavi N, Singh R (2000) Role of angiotensin II in diabetic nephropathy. *Kidney International* 58: S93-S98.
- 54 Zhao Y, Tan Y, Dai J, Li B, Guo L, et al. (2011) Exacerbation of diabetes-induced testicular apoptosis by zinc deficiency is most likely associated with oxidative stress, p38 MAPK activation, and p53 activation in mice. *Toxicol Lett* 200: 100-106.
- 55 Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. *The Journal of clinical investigation* 115: 1111-1119.
- 56 Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H (2009) Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. *World J Gastroenterol* 15: 280-288.
- 57 Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, et al. (2004) Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. *Am J Physiol Gastrointest Liver Physiol* 287: G1035-G1043.
- 58 Chiang DJ, Pritchard MT, Nagy LE (2011) Obesity, diabetes mellitus, and liver fibrosis. *Am J Physiol Gastrointest Liver Physiol* 300: G697-G702.
- 59 Li S, Wang L, Yan X, Wang Q, Tao Y, et al. (2012) Salvianolic Acid B Attenuates Rat Hepatic Fibrosis via Downregulating Angiotensin II Signaling. *Evid Based Complement Alternat Med* 2012: 160726.
- 60 Santos SH, Andrade JM, Fernandes LR, Sinisterra RD, Sousa FB, et al. (2013) Oral Angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF- κ B in rats fed with high-fat diet. *Peptides* 46: 47-52.
- 61 Wei S, Huang Q, Li J, Liu Z, You H, et al. (2012) Taurine attenuates liver injury by downregulating phosphorylated p38 MAPK of Kupffer cells in rats with severe acute pancreatitis. *Inflammation* 35: 690-701.
- 62 Thirunavukkarasu C, Watkins SC, Gandhi CR (2006) Mechanisms of endotoxin-induced NO, IL-6, and TNF-alpha production in activated rat hepatic stellate cells: role of p38 MAPK. *Hepatology* 44: 389-398.
- 63 Newton JF, Hoefle D, Gemborys MW, Mudge GH, Hook JB (1986) Metabolism and excretion of a glutathione conjugate of acetaminophen in the isolated perfused rat kidney. *J Pharmacol Exp Ther* 237: 519-524.
- 64 Granzow M, Schierwagen R, Klein S, Kowallick B, Huss S, et al. (2014) Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. *Hepatology* 60: 334-348.
- 65 Zhang K, Kaufman RJ (2008) From endoplasmic-reticulum stress to the inflammatory response. *Nature* 454: 455-462.
- 66 Ahsan R, Islam KM, Musaddik A, Haque E (2009) Hepatoprotective activity of methanol extract of some medicinal plants against carbon tetrachloride induced hepatotoxicity in albino rats. *Global J Pharmacol* 3: 116-122.
- 67 Muriel P (2009) Role of free radicals in liver diseases. *Hepatol Int* 3: 526-536.
- 68 Bieghs V, Trautwein C (2013) The innate immune response during liver inflammation and metabolic disease. *Trends Immunol* 34: 446-452.
- 69 Ueki M, Koda M, Yamamoto S, Matsunaga Y, Murawaki Y (2006) Preventive and therapeutic effects of angiotensin II type 1 receptor

- blocker on hepatic fibrosis induced by bile duct ligation in rats. *J Gastroenterol* 41: 996-1004.
- 70 Reza HM, Tabassum N, Sagor MA, Chowdhury MR, Rahaman M, et al. (2016) Angiotensin-converting enzyme inhibitor prevents oxidative stress, inflammation, and fibrosis in carbon tetrachloride-treated rat liver. *Toxicology Mechanisms and Methods* 26: 46-53.
- 71 Schnab B, Bradham CA, Bennett BL, Manning AM, Stefanovic B, et al. (2001) TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. *Hepatology* 34: 953-963.
- 72 Ramaiah SK, Jaeschke H (2007) Role of neutrophils in the pathogenesis of acute inflammatory liver injury. *Toxicol Pathol* 35: 757-766.
- 73 Rutault K, Hazzalin CA, Mahadevan LC (2001) Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha) mRNA induction. Evidence for selective destabilization of TNF-alpha transcripts. *J Biol Chem* 276: 6666-6674.
- 74 Dominguez C, Powers DA, Tamayo N (2005) p38 MAP kinase inhibitors: many are made, but few are chosen. *Curr Opin Drug Discov Devel* 8: 421-430.
- 75 Stebbins JL, De SK, Machleidt T, Becattini B, Vazquez J, et al. (2008) Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. *Proc Natl Acad Sci USA* 105: 16809-16813.
- 76 Heo YS, Kim SK, Seo CI, Kim YK, Sung BJ, et al. (2004) Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. *EMBO J* 23: 2185-2195.
- 77 Harris EH, Kerlund K, Tracey KJ, Wang H, Fehniger T, et al. (1999) Anti inflammatory effects of a new tumour necrosis factor-alpha (TNF- α) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats. *Clinical & Experimental Immunology* 115: 32-41.
- 78 Awad MM, Enslin H, Boylan JM, Davis RJ, Gruppuso PA (2000) Growth regulation via p38 mitogen-activated protein kinase in developing liver. *J Biol Chem* 275: 38716-38721.
- 79 Iwano S, Asaoka Y, Akiyama H, Takizawa S, Nobumasa H, et al. (2011) A possible mechanism for hepatotoxicity induced by BIRB-796, an orally active p38 mitogen-activated protein kinase inhibitor. *Journal of Applied Toxicology* 31: 671-677.
- 80 Strittmatter F, Walther S, Gratzke C, Göttinger J, Beckmann C, et al. (2012) Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3. *Br J Pharmacol* 166: 1926-1935.